0001213900-23-090209.txt : 20231127 0001213900-23-090209.hdr.sgml : 20231127 20231127160036 ACCESSION NUMBER: 0001213900-23-090209 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231127 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231127 DATE AS OF CHANGE: 20231127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inmune Bio, Inc. CENTRAL INDEX KEY: 0001711754 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 475205835 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38793 FILM NUMBER: 231440252 BUSINESS ADDRESS: STREET 1: 225 NE MIZNER BLVD, SUITE 640 CITY: BOCA RATON STATE: FL ZIP: 33432 BUSINESS PHONE: 8589643720 MAIL ADDRESS: STREET 1: 225 NE MIZNER BLVD, SUITE 640 CITY: BOCA RATON STATE: FL ZIP: 33432 8-K 1 ea189062-8k_inmunebio.htm CURRENT REPORT
0001711754 false 0001711754 2023-11-27 2023-11-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 27, 2023

 

INMUNE BIO INC.
(Exact name of registrant as specified in charter)

 

Nevada   001-38793   47-5205835
(State or other jurisdiction   (Commission File Number)   (IRS Employer
of incorporation)       Identification No.)

 

225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432

(Address of Principal Executive Offices) (Zip Code)

 

(858) 964 3720

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per shares   INMB   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01. Other Events.

 

On November 27, 2023, INmune Bio Inc. (the “Company”), issued a press release announcing that the Company has received European Medicines Agency’s Authorized Decision from the Agence Nationale de Securite du Medicament et des Produits de Sante in France and the Agencia Espanola de Medicamentos y Productos Sanitarios in Spain to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™.

 

A copy of the press release is attached herewith as Exhibit 99.1.

 

Item 9.01 Financial statements and Exhibits

 

(d) Exhibits.

 

99.1   Press Release dated November 27, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMUNE BIO INC.
   
Date: November 27, 2023 By: /s/ David Moss
    David Moss
    Chief Financial Officer

 

 

2

 

 EX-99.1 2 ea189062ex99-1_inmunebio.htm PRESS RELEASE DATED NOVEMBER 27, 2023

Exhibit 99.1

 

 

 

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

  

Boca Raton, Florida, Nov. 27, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company dedicated to advancing treatments that leverage the patient’s innate immune system to combat disease, announced today it has received European Medicines Agency’s (EMA) Authorized Decision from the Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM) in France and the Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) in Spain to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™.

 

This authorization follows the acceptance of the Company’s Clinical Trial Application (CTA) under EU Clinical Trials Regulation and prior EMA’s Authorized Decision in Poland on Nov 15, 2023.  The Spanish and French arms are part of the Company’s international clinical development strategy for XPro™ in patients with early AD. The trial is currently enrolling patients in Australia, Canada, and the United Kingdom.

 

“The French and Spanish clinical sites will significantly broaden the trial in Europe.  We are grateful for the collaboration from the ANSM and the AEMPS and look forward to continuing our progress toward completing enrollment of the Phase II trial.  We believe clinical sites in these two countries will be significant contributors to the Phase II program and will be part of the global Phase III clinical trial,” said RJ Tesi M.D., CEO of INmune Bio.

 

The Phase II clinical trial is a global, multi-center, randomized clinical study in patients diagnosed with early Alzheimer’s disease who have biomarkers of elevated inflammation. In a prior Phase I open-label trial, INmune Bio met all primary and secondary endpoints. Patients with AD who received XPro™ demonstrated notable decreases in neuroinflammation, enhanced axonal integrity, and improved synaptic function. Employing advanced MRI imaging techniques enabling a “virtual biopsy” of the brain, treatment with XPro™ demonstrated improvements in the structural integrity of both gray and white matter in the brain.

 

About XPro™

 

XPro™ (XPro1595, pegipanermin) is a next-generation selective inhibitor of tumor necrosis factor (TNF) that is currently in clinical trials and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro™ could potentially have substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation, decreasing neurodegeneration while improving synaptic function and promoting remyelination. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website.

 

 

 

About INmune Bio, Inc.

 

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Early Alzheimer’s disease, and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.

 

Forward Looking Statements

 

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595 (XPro™), and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

 

INmune Bio Contact:

 

David Moss, CFO (858) 964-3720
info@inmunebio.com

 

Investor Contact:

 

Jason Nelson
Core IR
(516) 842-9614 x-823

 

 

 

 

 

 EX-101.SCH 3 inmb-20231127.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 inmb-20231127_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 inmb-20231127_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 27, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 27, 2023
Entity File Number 001-38793
Entity Registrant Name INMUNE BIO INC.
Entity Central Index Key 0001711754
Entity Tax Identification Number 47-5205835
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 225 NE Mizner Blvd.
Entity Address, Address Line Two Suite 640
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33432
City Area Code 858
Local Phone Number 964 3720
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per shares
Trading Symbol INMB
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 ea189062-8k_inmunebio_htm.xml IDEA: XBRL DOCUMENT 0001711754 2023-11-27 2023-11-27 iso4217:USD shares iso4217:USD shares 0001711754 false 8-K 2023-11-27 INMUNE BIO INC. NV 001-38793 47-5205835 225 NE Mizner Blvd. Suite 640 Boca Raton FL 33432 858 964 3720 false false false false Common Stock, par value $0.001 per shares INMB NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmunebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea189062-8k_inmunebio.htm inmb-20231127.xsd inmb-20231127_lab.xml inmb-20231127_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea189062-8k_inmunebio.htm": { "nsprefix": "INMB", "nsuri": "http://inmunebio.com/20231127", "dts": { "inline": { "local": [ "ea189062-8k_inmunebio.htm" ] }, "schema": { "local": [ "inmb-20231127.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "inmb-20231127_lab.xml" ] }, "presentationLink": { "local": [ "inmb-20231127_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://inmunebio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea189062-8k_inmunebio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea189062-8k_inmunebio.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inmunebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001213900-23-090209-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-090209-xbrl.zip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end